Unibest
← Back to patent-cliff list

CAS 21739-92-4

5-bromo-2-chlorobenzoic acid

Codes: EMPA-001, DAPA-001

Application context (from source-drug indications)

Chronic renal impairmentEmpagliflozinHeart failureEmpagliflozinType 2 diabetesEmpagliflozinType 2 diabetesDapagliflozin Propanediol/Metformin HydrochlorideChronic renal impairmentDapagliflozin Propanediol MonohydrateHeart failureDapagliflozin Propanediol MonohydrateKidney diseaseDapagliflozin Propanediol MonohydrateType 1 diabetesDapagliflozin Propanediol MonohydrateType 2 diabetesDapagliflozin Propanediol MonohydratePolycystic ovary syndromeDapagliflozin Propanediol Monohydrate

Source drugs (routes using this intermediate)

DrugTierExpiry
EmpagliflozinTier A — Act now2028
Dapagliflozin Propanediol/Metformin HydrochlorideTier A — Act now2030
Dapagliflozin Propanediol MonohydrateTier B — Position early-

Position in synthesis routes (up/downstream chain)

Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.

Intermediates available on this site

Side-by-side comparison of all listed offers on this CAS; price bands are list-price ranges, final price subject to RFQ confirmation.

SupplierProductPrice bandMOQLead timeQualificationsAction
Unibest Nantong cGMP Site5-Bromo-2-chlorobenzoic acid
Pharmaceutical Intermediates
On requestOn requestOn request
—

This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.